TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Benign Prostatic Hyperplasia, based on medical history~* Voiding symptoms~Exclusion Criteria:~* Urgent need for prostate surgery or prior surgical treatment of the prostate or bladder~* Major organ dysfunction~* Eczema (atopic dermatitis) treated during the last 6 months~* Current or recent treatment with sexual hormone drugs or 5 α reductase inhibitors or botulinum toxin type a (Botox) within the last 6 months prior randomization or with α blockers or saw palmetto within the last 6 weeks prior to randomization~* Urologic disorders including neurogenic bladder dysfunction due to diabetes mellitus or documented neurologic disorder, urethral stricture disease or history of pelvic radiation therapy~* History of acute obstructive, infectious, or neurological disorders of the genitourinary tract within the last 3 months

- Gender: MALE
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment Group A: CET 78 mg + 78 mg (Type: EXPERIMENTAL): Treatment course 1: Cetrorelix 78 mg + 78 mg~* Week 0: 52 mg CET (2 injections)~* Week 2: 26 mg CET (1 injection)~Treatment course 2:~* Week 26: 52 mg CET (2 injections)~* Week 28: 26 mg CET(1 injection)~  4 days with treatment, Day 1 of each indicated week, 6 injections in total per patient.
- Treatment Group B: CET 78 mg + 52 mg (Type: EXPERIMENTAL): Treatment course 1: Cetrorelix 78 mg + 52 mg~* Week 0: 52 mg CET (2 injections)~* Week 2: 26 mg CET (1 injection)~Treatment course 2:~* Week 26: 52 mg CET (2 injections)~* Week 28: Placebo (1 injection)~  4 days with treatment, Day 1 of each indicated week, 6 injections in total per patient.
- Treatment Group C: Placebo (Type: PLACEBO_COMPARATOR): Treatment course 1:~* Week 0: placebo (2 injections)~* Week 2: placebo (1 injection)~Treatment course 2:~* Week 26: placebo (2 injections)~* Week 28: placebo (1 injection)~  4 days with treatment, Day 1 of each indicated week, 6 injections in total per patient.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Low-intensity Extracorporeal Shock Wave for Erectile Disfunction

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* patients over 18 years of age~* clinical diagnosis of organic vascular ED of more than three months and with an erection hardness score (EHS) of three or less~Exclusion Criteria:~* patients with ED caused by side effects from drugs or spinal cord injury~* situational ED (obvious psychological origin)~* lesions, loss of skin or penile implant~* patients who did not adequately complete the LI-ESWT

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Cognitive Motor Therapy Applications Using Videogame Platform

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* New onset stroke~* Ability to follow one-step commands~  * All participants must be admitted to the inpatient rehabilitation unit at Cedars-Sinai Medical Center~ * Scores needed for Participation in Study on the Complex Ideational Material-Short Form from the Boston Diagnostic Aphasia Examination and the Montreal Cognitive Assessment:~* Complex Ideational Material-Short Form from the Boston Diagnostic Aphasia Examination-Participants must obtain a total score of at least 5/6 item pairs to participate~* Montreal Cognitive Assessment-Participants must obtain a total score of 16 or greater and obtain a score of 6/6 on the orientation subtest~* In order to participate, participants must meet both of the above criteria~Exclusion Criteria:~* Patients who do not meet inclusion criteria as noted above.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standardized Assessments (Type: ACTIVE_COMPARATOR): Standardized Assessments (paper and pencil tests) to be given to each participant. The standardized assessments will be completed in paper and pencil format. These tests include:~* Line Bisection Test~* Patient Reported Outcomes~* Trial Making A and B~* Usability Questionnaire
- Videogame Assessments (Type: EXPERIMENTAL): Videogame assessments will be performed by each participant using videogames. The videogame assessments will be performed using videogames on a tabletop platform with touchscreen which includes:~* Line Crossing~* Patient Reported Outcomes~* Trial Making A \& B-Asteroid Adventure Game~* Usability Questionnaire

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Learning Curve to Anchor GYN-CS® Device

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Generally healthy, women,~* Pregnant women in the second trimester~* 18-48 years of age~* Birth by Caesarean section planned~* Be willing to stay in the study for 3 years~* Return for follow-up at the designated times~* Signed informed consent~Exclusion Criteria:~* The presence of infection of the uterus, clinical cervicitis or vaginitis (infection should be ruled out)~* Suspicion of endometrial or uterine pathology such as congenital malformation of the uterus~* Large uterine fibromata (\> 3 cm in diameter)~* Acute leukemia~* Severe blood clotting disorders and undiagnosed genital tract bleeding~* Significant medical disease that in the medical opinion of the investigator is likely to interfere with patient ability to complete the entire trial~* Participants receiving corticosteroid therapy (hydrocortisone\>40mg/d or an equivalent) or immunosuppressive drugs~* Caesarean section \< 36 weeks

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 48 Years
- Healthy Volunteers: t

Study Arms:
- GYN-CS insertion (Type: OTHER): GYN-CS device will be inserted in women during their c-section. The study patient can chose between a lifespan of 3 years (GYN-CS 3) and a lifespan of 10 years (GYN-CS 10) of the device.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Electroacupuncture on Post-stroke Urinary Retention

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* male or female aged over 19~* Patients diagnosed with stroke (cerebral hemorrhage or infarction) based on the CT or MRI examination~* Those whose onset is within 2 years~* Those who have urinary retention after stroke onset (every PVR result is equal or more than 100ml on the 2 consecutive tests)~* Those who signed on the informed consent form~Exclusion Criteria:~* Patients who have any bleeding disorders based on medical history hearing~* Patients who have ever had any medical procedures or surgeries for peripheral vascular diseases based on medical history hearing~* Patients who have any psychiatry disorders based on medical history hearing~* Patients who have any severe diseases in lower urinary tract symptom based on medical history hearing~* Patients who have any acute or chronic infectious diseases in lower urinary tract symptom based on medical history hearing~* Acute stage stroke patients (onset within 1 week) whose Glasgow Coma Scale ≤ 8~* Patients who have fear about acupuncture~* Patients who have changed medications for urinary retention or relevant symptoms, such as urinary incontinence drugs or diuretics, within 3 days~* Female who diagnosed with pregnancy by urinalysis~* Those who primary or sub investigators judge not to be suitable for the study

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Electroacupuncture (EA) group (Type: EXPERIMENTAL): 1. Electroacupuncture therapy (10 sessions in total, 5 per a week, 2 weeks)~2. BL31, BL32, BL33, and BL34 (total 8 acupoints, bilateral)~3. 20 minutes duration, middle frequency (30 Hz) of electrical stimulation~4. conventional treatments permitted
- Sham group (Type: SHAM_COMPARATOR): 1. Non-penetrating Park sham electroacupuncture treatment (10 sessions in total, 5 per a week, 2 weeks)~2. BL31, BL32, BL33, and BL34 (total 8 acupoints on the right and left sides)~3. 20 minutes duration, undelivered electrostimulation of middle frequency (30 Hz)~4. conventional treatments permitted

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: SHERLOCK 3CG™ Diamond Tip Confirmation System

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male or female, ≥ 21 years of age with altered cardiac rhythm (no recognizable P-wave on standard ECG) with diagnosis of specific arrhythmia type or identification of pacemaker driven rhythms as defined below:~  1. Atrial fibrillation with history of diagnosis per 12-lead ECG in medical record or diagnosed via bedside telemetry by study team RN at assessment, or~ 2. All other arrhythmias (including but not limited to atrial flutter, PAC, PVC, PJC, tachycardia, AV Block, BB Block) with history of diagnosis per 12-lead ECG in medical record or diagnosed via bedside telemetry by cardiac unit RN at assessment, or retrospectively by site cardiologist, or~ 3. Pacemaker driven rhythm with temporary or permanent pacemaker device in place;~* Subject requires PICC placement as part of standard of care;~* Subject or Legally Authorized Representative (LAR) has signed an Informed Consent Form (ICF).~Exclusion Criteria:~* Subject has a contraindication to PICC placement as listed in the Instructions for Use (IFU) to include:~  1. The presence of bacteremia or septicemia (known or suspected),~ 2. The patient's body size is insufficient to accommodate the size of the implanted device,~ 3. The patient is known or is suspected to be allergic to materials contained in the device,~ 4. Past irradiation of prospective insertion site,~ 5. Previous episodes of venous thrombosis or vascular surgical procedures at the prospective placement site,~ 6. Local tissue factors will prevent proper device stabilization and/or access;~* Subjects who previously had a PICC in place and require a PICC exchange;~* Subject has presence of active resting tremor (i.e. Parkinson's, Multiple Sclerosis, etc.) deemed by Investigator to have potential impact on procedure accuracy;~* Subjects who are pregnant or think they may be pregnant.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PICC Placement with Study Device (Type: None): PICC Placement with SHERLOCK 3CG™ Diamond TCS with MODUS II software

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Safety and Efficacy of AVE5530 as add-on to Ongoing High Doses of Statins in Patients With Primary Severe Hypercholesterolemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adults with severe primary hypercholesterolemia and cholesterol levels not controlled on ongoing stable statin treatment at maximum doses.~Exclusion Criteria:~* LDL-C levels \> 250 mg/dL (6.48 mmol/L) or \< 100 mg/dL (2.59 mmol/L)~* Triglycerides \>350 mg/dL (3.95 mmol/L)~* Conditions / situations such as:~  * Presence of any clinically significant uncontrolled endocrine disease known to influence lipids levels~ * Active liver disease~ * Recent history of congestive heart failure, of unstable angina pectoris, myocardial infarction, coronary bypass surgery or angioplasty, or Unstable or severe peripheral artery disease~ * Positive test for Hepatitis B surface antigen and/or Hepatitis C antibody or Known to be Human Immunodeficient Virus (HIV) positive~* Pregnant or breast-feeding women,~* Women of childbearing potential not protected by effective contraceptive method of birth control (including oral contraceptives) and/or who are unwilling or unable to be tested for pregnancy prior to exposure to the Investigational Product~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 25 mg/day AVE5530 (Type: EXPERIMENTAL): None
- 50 mg/day AVE5530 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Flavopiridol in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed B-cell chronic lymphocytic leukemia (CLL) or prolymphocytic leukemia (PLL) arising from CLL~  * No de novo PLL~ * Lymphocyte count \> 5,000/mm\^3 at some point since initial diagnosis of CLL~ * B-cells co-expressing CD5 AND CD19 or CD20~ * If no dim serum immunoglobulin or CD23 expression on leukemia cells, must be examined for cyclin D1 overexpression OR t(11;14) to rule out mantle cell lymphoma~* Requiring therapy, defined by any of the following:~  * Massive or progressive splenomegaly and/or lymphadenopathy~ * Anemia (hemoglobin \< 11 g/dL) OR thrombocytopenia (platelet count \< 100,000/mm\^3)~ * Weight loss \> 10% within the past 6 months~ * Grade 2 or 3 fatigue~ * Fevers \> 100.5°C or night sweats for \> 2 weeks with no evidence of infection~ * Progressive lymphocytosis with an increase of \> 50% over a 2-month period OR an anticipated doubling time \< 6 months~* Received ≥ 1 prior chemotherapy regimen that included fludarabine or nucleoside equivalent OR alternative therapy if contraindication to fludarabine exists (i.e., autoimmune hemolytic anemia)~* Performance status - ECOG 0-2~* More than 2 years~* See Disease Characteristics~* Baseline cytopenias allowed~* WBC ≤ 200,000/mm\^3~* Bilirubin ≤ 1.5 times upper limit of normal (ULN) (unless due to Gilbert's disease, hemolysis, or disease infiltration of the liver)~* AST ≤ 2 times ULN (unless due to hemolysis or disease infiltration of the liver)~* Creatinine ≤ 2.0 mg/dL~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No other malignancy that would limit life expectancy~* See Disease Characteristics~* No other concurrent chemotherapy~* No concurrent chronic corticosteroids or corticosteroids as antiemetics~* No concurrent hormonal therapy except steroids for new adrenal failure or hormones for nondisease-related conditions (e.g., insulin for diabetes)~* No concurrent radiotherapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (alvocidib) (Type: EXPERIMENTAL): Patients receive flavopiridol IV over 30 minutes followed by a 4-hour infusion on days 1, 8, 15, and 22. Treatment repeats every 42 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients achieving at least a partial remission (PR) and whose PR lasts for \> 6 months after completion of treatment may receive 6 additional courses of flavopiridol.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Assessment of Vulnerability to Carotid Stenosis by MultiModal Imaging and Cellular and Molecular Biology Analysis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with symptomatic or asymptomatic atheromatous stenosis of the internal carotid artery, of a degree ≥ 50%, for which an operative indication is retained~* Scheduled surgery~Exclusion Criteria:~Samples collected from patients :~* who did not have a preoperative CT angiogram of the supra-aortic trunks~* with contraindication to MRI~* with contraindication to PET scan~* with a history of cervical radiotherapy~* with uncontrolled diabetes~* with a previous homolateral carotid endarterectomy~* who has already undergone angioplasty-stenting of the homolateral carotid artery~* with a neoplasia considered active / not cured~* Surgical procedure performed in emergency

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patient with atheromatous stenosis of the internal carotid artery (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: PF-07304814 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria: Refer to the master protocol (NCT04501978)~Exclusion Criteria: Refer to the master protocol (NCT04501978)~Additional Exclusion Criteria:~1. Participants with moderate to severe hepatic impairment (i.e. Child-Pugh class B or C) or acute liver failure.~2. Participants receiving any medications or substances that are strong inhibitors or inducers of cytochrome P450 (CYP) 3A4 (see Section H6.3.4).~3. Patients will be excluded if taking drugs which have a narrow therapeutic window that are substrates of CYP3A4, including but not limited to: astemizole, cisapride, cyclosporine, dihydroergotamine, ergotamine, pimozide, quinidine, sirolimus, tacrolimus, and terfenadine.~4. Pregnant women~5. Nursing mothers~6. Women of child-bearing potential who are unwilling to acknowledge the strong advice to abstain from sexual intercourse with men or practice appropriate contraception through 5 weeks of the study.~7. Men who are unwilling to acknowledge the strong advice to abstain from sexual intercourse with women of child-bearing potential or to use barrier contraception through 5 weeks of the study.~8. Patients with a history of deep vein thrombosis or pulmonary thrombotic embolism\*.~   * Prior to the initial futility assessment, which is performed when approximately 150 patients have been enrolled on PF-07304814 and 150 on placebo, patients with a history of deep vein thrombosis or pulmonary embolism will be excluded. These patients will be eligible for the trial if the initial futility assessment is passed by this agent, and if risk-benefit is favorable based on an assessment of available data that is reviewed by the independent DSMB. These data will include treatment comparisons of thromboembolic events and coagulation markers, and any additional data from studies carried out by Pfizer.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PF-07304814 plus SOC (Type: EXPERIMENTAL): * PF-07304814 250 mg per day for 5 days; administered as a constant rate IV infusion~* Remdesivir is provided to all study participants as SOC unless contraindicated for an individual patient; administered by IV infusion
- Placebo plus SOC (Type: PLACEBO_COMPARATOR): * Placebo administered by IV infusion~* Remdesivir is provided to all study participants as SOC unless contraindicated for an individual patient; administered by IV infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval